DSBio Consulting LLC
Consulting firm providing advisory and management services for biomedical technology development with a focus on health security and public‑health diagnostics. Services include technology readiness assessment, funding and solicitation navigation, proposal development, regulatory strategy for FDA authorization/approval, and program/project management. The founder has prior leadership roles in U.S. government health security programs and involvement in BARDA and COVID‑19 diagnostic acceleration efforts.
Industries
N/A
Nr. of Employees
small (1-50)
Services
Consultation to assess technology maturity and alignment with funder and partner requirements; includes a project plan with timelines and milestones.
Identify funding opportunities, interpret solicitations, and support proposal preparation for mechanisms such as RFPs, BAAs, SBIR and STTR.
Advise on regulatory pathways toward FDA authorization/approval and on commercialization, procurement, and distribution considerations.
Management support for government‑funded programs and rapid response efforts, including schedule, milestones, and contractor coordination.
Consultation to assess technology maturity and alignment with funder and partner requirements; includes a project plan with timelines and milestones.
Identify funding opportunities, interpret solicitations, and support proposal preparation for mechanisms such as RFPs, BAAs, SBIR and STTR.
Advise on regulatory pathways toward FDA authorization/approval and on commercialization, procurement, and distribution considerations.
Management support for government‑funded programs and rapid response efforts, including schedule, milestones, and contractor coordination.
Expertise Areas
- Health security and biodefense program management
- Diagnostic assay validation and deployment
- Technology readiness assessment and evaluation
- Funding and solicitation strategy (RFP/BAA, SBIR/STTR)
Key Technologies
- Diagnostic assay validation
- Technology readiness level (TRL) assessment
- Regulatory submission strategy (FDA authorization/approval)
- Grant and solicitation strategy (RFP/BAA, SBIR/STTR)
News & Updates
Founder involvement in the 2018 launch of a BARDA program to address gaps in preparedness and accelerate innovative solutions.
Programs led by the founder supported expedited validation and distribution of FDA‑authorized COVID‑19 diagnostic tests in 2020.
Founder involvement in the 2018 launch of a BARDA program to address gaps in preparedness and accelerate innovative solutions.
Programs led by the founder supported expedited validation and distribution of FDA‑authorized COVID‑19 diagnostic tests in 2020.